MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside

Analysts have lifted the implied fair value estimate for Moderna shares by about $7, citing a reset in litigation risk following the Arbutus and Genevant settlement and refreshed expectations for the flu and broader vaccine pipeline that flow through to higher modeled revenue growth and a richer future P/E multiple.

Analyst Commentary

Street research on Moderna has been active, with several firms revisiting their models after the Arbutus and Genevant settlement, the Q4 earnings update, and the FDA's decision to review the mRNA-1010 flu vaccine. Taken together, these views present a mixed picture that balances optimism on the pipeline and litigation reset with caution around execution, revenue visibility, and valuation.

Bullish Takeaways

Bullish analysts see the $2.3b settlement as reducing a major overhang on the shares. They frame the outcome as better than a worst case and helpful for clearing litigation uncertainty that had weighed on valuation multiples.
Several firms lifted price targets, citing refreshed models after Q4 that factor in Moderna's guidance for 2026, ex US expansion, and a broader vaccine pipeline. In their view, this feeds into higher implied P/E and revenue assumptions.
The FDA reversal to accept the mRNA-1010 BLA for review and set an August 5 PDUFA date is viewed as clearly positive. Some bullish analysts highlight that the large 43,808 patient trial met all primary endpoints and outperformed high dose comparators, which they see as supporting confidence in medium term flu revenue contribution.
Oncology programs, including the INT cancer program and adjuvant melanoma Phase 3 data expected in the next couple of years, are seen by some as potential swing factors. In their view, these could materially influence Moderna's earnings mix and justify richer valuation multiples if execution stays on track.

Bearish Takeaways

Bearish analysts maintain Underperform or equivalent ratings even after lifting price targets. They argue that the litigation settlement still leaves a contingent tail with up to US$1.3b in additional payments tied to appeal outcomes, which they treat as a continuing risk for valuation.
Some remain cautious on mRNA-1010 and describe the path ahead as unclear despite the FDA's acceptance. They flag ongoing debate about comparators in older adults, which in their models limits assumed flu market penetration and keeps overall revenue and P/E expectations restrained.
Several Neutral and Equal Weight ratings emphasize that, despite updated Q4 models and higher targets, they await clearer evidence of a sustained top line re inflection. They treat current guidance for 2026 revenue and oncology progress as needing more proof before moving off the sidelines.
Even with raised targets clustered around US$27 to US$45, some research points to Moderna's cash use and dependence on a few key programs. They also cite the removal of "near term upside catalysts" after the settlement as reasons to maintain more conservative views on growth and execution risk.

What’s in the News

Genevant Sciences and Arbutus Biopharma agreed to a US$2.25b global settlement with Moderna that resolves U.S. and international patent enforcement actions over lipid nanoparticle delivery technology used in Moderna’s COVID 19 vaccines, with US$950m due upfront in July 2026 and up to US$1.3b contingent on the outcome of an appeal on U.S. government liability, alongside a global non exclusive license for infectious disease applications (company disclosure).
Moderna received a Refusal to File letter from the FDA’s Center for Biologics Evaluation and Research for its mRNA 1010 influenza vaccine BLA, with the agency citing the choice of a standard dose comparator rather than a best available high dose vaccine as the reason, while not flagging specific safety or efficacy concerns and leaving Moderna’s 2026 guidance unchanged (company disclosure).
Moderna issued 2026 guidance that points to total revenue growth of up to 10% and a revenue profile weighted toward the second half of the year, with an estimated 15% in the first half and 85% in the second half and a geographic mix that is expected to be more balanced between the U.S. and ex U.S. markets (company disclosure).
From October 1, 2025 to December 31, 2025, Moderna reported no additional share repurchases, completing a total of 9,530,147 shares bought back for US$1,337.93m under the August 3, 2022 authorization, equal to 2.48% of shares (company disclosure).
Media reports highlighted internal FDA tensions around Moderna’s mRNA flu application, including accounts that Center Director Vinay Prasad overruled FDA reviewers who were prepared to evaluate the filing and separate reporting that Prasad is leaving the agency, developments that could affect how investors think about future vaccine reviews involving Moderna (STAT, New York Times).

Valuation Changes

Fair Value: Raised from $38.8 to $46.1, which points to a richer implied equity valuation in updated models.
Discount Rate: Adjusted slightly higher from 7.09% to 7.25%, indicating a modestly higher required return in the cash flow framework.
Revenue Growth: Assumed long term growth rate increased from 11.47% to 17.91%, reflecting stronger modeled top line expansion.
Net Profit Margin: Reduced from 16.96% to 12.78%, with analysts now incorporating a slimmer earnings margin on projected revenue.
Future P/E: Target future P/E multiple lifted from 36.8x to 58.7x, implying a higher valuation placed on projected earnings in the outer years.

19 views

Key Takeaways

Expansion of the mRNA pipeline and strong regulatory engagement are set to diversify revenue and accelerate commercialization across infectious diseases and oncology.
Cost-cutting measures, AI adoption, and stable government contracts are driving margin improvement, operational efficiency, and more predictable revenue streams.
Slowing vaccine sales, higher competition, cost cuts, regulatory pressures, and limited capital flexibility threaten Moderna's revenue stability, pipeline breadth, and long-term earnings growth.

Catalysts

About Moderna

A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.What are the underlying business or industry changes driving this perspective?

The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID-19-including recent positive late-stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases-are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top-line growth.
Regulatory momentum and robust relationships with agencies (as reflected in multiple recent FDA approvals and ongoing engagement for pipeline submissions) position the company to benefit from accelerated approval pathways, enabling faster commercialization of innovative products and unlocking earlier revenue streams.
Cost structure transformation-including significant workforce reductions, manufacturing and procurement efficiencies, and ongoing R&D prioritization-puts Moderna on course to more than halve operating expenses by 2027 and target cash breakeven by 2028, driving considerable improvements in net margins and future earnings leverage.
Increasing adoption of AI and advanced analytics throughout the organization is expected to accelerate R&D productivity, speed up drug discovery, and enable more efficient commercialization, supporting both margin expansion and pipeline success in a sector being transformed by digital innovation.
Stable government and advanced purchase agreements for vaccines, combined with sustained investment in pandemic preparedness and biosecurity, create durable and predictable revenue channels amid uncertainty in vaccination rates, while also supporting Moderna's positioning as a rapid-response partner for public and private health needs.

Moderna Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Moderna's revenue will grow by 17.9% annually over the next 3 years.
Analysts are not forecasting that Moderna will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Moderna's profit margin will increase from -145.2% to the average US Biotechs industry of 12.8% in 3 years.
If Moderna's profit margin were to converge on the industry average, you could expect earnings to reach $407.1 million (and earnings per share of $0.97) by about April 2029, up from -$2.8 billion today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 58.8x on those 2029 earnings, up from -7.1x today. This future PE is greater than the current PE for the US Biotechs industry at 17.8x.
Analysts expect the number of shares outstanding to grow by 2.12% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.25%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Sustained decline in COVID-19 vaccine revenues and continued seasonality in the respiratory vaccine portfolio expose Moderna to ongoing revenue volatility, with pipeline diversification and non-seasonal products not yet adequately compensating for this downturn; this may result in pressure on both revenue growth and earnings consistency if replacement products underperform.
Intensifying competitive pressures in both the COVID-19 and RSV vaccine markets, coupled with uncertainty in vaccination rates and pricing (especially in the U.S.), threaten Moderna's ability to maintain market share and realize premium pricing, which could compress revenues and net margins over time.
Heavy reliance on cost reduction strategies-including significant R&D cuts, portfolio prioritization, and a 10% workforce reduction-risks constraining future innovation and pipeline productivity if new launches or late-stage program results disappoint, potentially resulting in persistent net losses and margin weakness.
Increasing regulatory scrutiny and shifting government policies, particularly on drug pricing, reimbursement, and approval requirements (noted across the company's remarks regarding evolving regulatory interactions), could delay new product launches, limit pricing power, and further compress profit margins, negatively impacting future earnings.
The company's strategy to seek external partners or financing (rather than self-funding) for key pipeline assets in high-potential but expensive clinical areas (like latent vaccines and rare diseases) reflects limited internal capital flexibility; this may restrict long-term pipeline breadth, reduce the probability of blockbuster diversification, and ultimately limit long-term revenue growth and earnings potential.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $46.1 for Moderna based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $135.0, and the most bearish reporting a price target of just $21.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.2 billion, earnings will come to $407.1 million, and it would be trading on a PE ratio of 58.8x, assuming you use a discount rate of 7.2%.
Given the current share price of $50.73, the analyst price target of $46.1 is 10.0% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Moderna?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts